{"id":"terlipressin-plus-standard-care","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2135460","moleculeType":"Protein","molecularWeight":"1227.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating vasopressin receptors, leading to increased blood pressure and reduced portal blood flow. This mechanism is particularly useful in treating conditions like hepatorenal syndrome.","oneSentence":"Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:04.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatorenal syndrome"}]},"trialDetails":[{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07131306","phase":"PHASE2","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2027-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":100},{"nctId":"NCT07075315","phase":"PHASE3","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2028-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":100},{"nctId":"NCT05346393","phase":"NA","title":"HRS-AKI Treatment With TIPS in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2022-11-29","conditions":"Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury","enrollment":124},{"nctId":"NCT04112199","phase":"PHASE2","title":"A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites","status":"TERMINATED","sponsor":"BioVie Inc.","startDate":"2021-06-17","conditions":"Ascites, Decompensated Cirrhosis","enrollment":15},{"nctId":"NCT04819568","phase":"NA","title":"Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2021-06-25","conditions":"Liver Cirrhosis","enrollment":310},{"nctId":"NCT05080543","phase":"PHASE1","title":"Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients","status":"UNKNOWN","sponsor":"Amany Mousa Salama Muhammed","startDate":"2021-10","conditions":"Septic Shock","enrollment":36},{"nctId":"NCT04948372","phase":"NA","title":"Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-09-01","conditions":"Septic Shock","enrollment":22},{"nctId":"NCT04221672","phase":"PHASE3","title":"The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-11-07","conditions":"Terlipressin Adverse Reaction, Ascites Hepatic, Liver Failure","enrollment":86},{"nctId":"NCT04028505","phase":"PHASE3","title":"Terlipressin Infusion in Variceal Hemorrhage","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2018-10-25","conditions":"Terlipressin Adverse Reaction","enrollment":128},{"nctId":"NCT02377141","phase":"NA","title":"Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-04-18","conditions":"Liver Cirrhosis, Variceal Haemorrhage","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["terlipressin infusion plus routine care"],"phase":"phase_3","status":"active","brandName":"Terlipressin plus standard care","genericName":"Terlipressin plus standard care","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor. Used for Hepatorenal syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}